Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances, whereby Vicore Pharma receives gross proceeds of SEK 500 million.

The share issuances were directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is conditional upon approval by an extraordinary general meeting and that a prospectus is published. Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).

Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.

Related

Vinge has advised Advania on the acquisition of Visuell Teknik

Advania has acquired Visuell Teknik, a Swedish provider of audiovisual and meeting technology solutions.
October 28, 2025

Vinge has advised Acrinova in connection with voluntary share redemption offering

Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Lejon Entreprenad

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Lejon Entreprenad, a well-established specialist company offering qualified services within surface treatment, including industrial painting, anti-corrosion painting, and FROSIO inspections.
October 27, 2025